12 completed, 7 recruiting, 4 active not recruiting, 4 terminated. 23 Phase 2, 7 Phase 1, 2 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow Rabbit ATG: new trials by email Literature Review of Rabbit ATG trials Research Report on Rabbit ATG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allo HSCT for High Risk Hemoglobinopathies Alemtuzumab, Total Body Irradiation, Cell Infusion - Graft Failure, Sickle Cell Disease | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 62 | 2024-11-19 | 2026-06-04 |
| MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. Rituximab, Rabbit ATG, Cyclophosphamide - Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 60 | 2024-06-05 | 2026-06-03 |
| Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Aspiration, Busulfan - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 66 | 2023-03-15 | 2026-07-30 |
| A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) Fludarabine, Cyclophosphamide, Tacrolimus - Sickle Cell Disease, Thalassemia, Beta | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 24 | 2023-02-09 | 2026-06-03 |
| Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) Treosulfan, Fludarabine Phosphate, Tacrolimus - Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 40 | 2022-04-19 | 2026-03-09 |
| Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders Fludarabine, Dexamethasone, Cyclophosphamide - Stem Cell Transplantation | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-03-02 | 2023-09-21 | |
| Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) Anti-thymocyte globulin (rabbit), Busulfan, Fludarabine - Severe Combined Immunodeficiency | Phase 1 / Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 4 | 2021-09-02 | 2026-09-16 |
| Haploidentical HCT for Severe Aplastic Anemia Anti-Thymocyte Globulin (Rabbit), Fludarabine, Cyclophosphamide - Aplastic Anemia, Bone Marrow Failure Syndrome | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 21 | 2021-01-21 | 2026-09-16 |
| Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer Etoposide, Fludarabine Phosphate, Hematopoietic Cell Transplantation - Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2021-01-14 | 2024-10-26 | |
| Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies Bortezomib, Busulfan, Cyclophosphamide - Beta Thalassemia Major, Sickle Beta 0 Thalassemia | Early Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2020-12-29 | 2024-10-24 | |
| Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide - Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 2 | Terminated | M.D. Anderson Cancer Center | 1 | 2020-08-19 | 2025-06-29 |
| Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Fludarabine, Cyclophosphamide - Non-Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 40 | 2020-06-16 | 2026-06-17 |
| Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Rabbit ATG - aGVHD, cGVHD | Phase 2 | Unknown | Chinese PLA General Hospital | 60 | 2019-02-01 | 2022-02-22 |
| A Blood Stem Cell Transplant for Sickle Cell Disease Cyclophosphamide, Pentostatin, Rabbit anti-thymocyte globulin - Sickle Cell Disease, Sickle Cell Disorder | Phase 1 | Active not recruiting | City of Hope Medical Center | 3 | 2019-01-04 | 2026-03-05 |
| Romidepsin Maintenance After Allogeneic Stem Cell Transplantation Romidepsin, Busulfan, Fludarabine - Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 23 | 2017-12-08 | 2025-09-19 |
| Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Fludarabine, Cyclophosphamide, Total Body Irradiation - Severe Aplastic Anemia | Phase 2 | Recruiting | Northside Hospital, Inc. | 20 | 2016-09-09 | 2026-10-14 |
| Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Fludarabine, Busulfan, Rabbit ATG - Leukemia, Lymphoid, Leukemia, Myeloid | Phase 1 | Completed | Dartmouth-Hitchcock Medical Center | 20 | 2016-09-06 | 2023-10-18 |
| Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Anti-thymocyte globulin (rabbit), Blinatumomab, Cyclophosphamide - Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 170 | 2016-07-14 | 2025-08-12 |
| Effects of Inhibiting Early Inflammation in Kidney Transplant Patients Infliximab, Methylprednisolone, Mycophenolate Mofetil - Kidney Transplant | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 290 | 2015-11-02 | 2026-09-24 |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) Busulfan, Fludarabine, Clofarabine - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 11 | 2015-09-14 | 2024-02-22 |
Showing 20 of 32. Sign in to see all of them.
Leukemia, Myeloid, Acute (10) · Myelodysplastic Syndromes (8) · Anemia, Aplastic (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia (5) · Lymphoma (5) · Lymphoma, Non-Hodgkin (5) · Anemia, Sickle Cell (4) · Hemoglobinuria, Paroxysmal (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Leukemia, Myelomonocytic, Juvenile (3) · Anemia, Refractory, with Excess of Blasts (2) · Bone Marrow Failure Disorders (2) · Hemoglobinopathies (2) · Hodgkin Disease (2)
M.D. Anderson Cancer Center (6) · St. Jude Children's Research Hospital (5) · Masonic Cancer Center, University of Minnesota (4) · Children's Oncology Group (2) · Fred Hutchinson Cancer Center (2) · Children's Hospital Medical Center, Cincinnati (1) · Chinese PLA General Hospital (1) · City of Hope Medical Center (1) · Dartmouth-Hitchcock Medical Center (1) · Gang Chen (1) · Memorial Sloan Kettering Cancer Center (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Blood Disease Center, Pakistan (1) · Northside Hospital, Inc. (1) · Novartis Pharmaceuticals (1)
United States (26) · Canada (3) · China (2) · Australia (1) · Japan (1) · Pakistan (1)
Brandon Triplett, MD (2) · Akshay Sharma, MBBS (1) · Amr Qudeimat, MD (1) · Brandon M. Triplett, MD (1) · Daihong Liu, Doctor (1) · Donald E Hricik, MD (1) · Ewelina Mamcarz, MD (1) · Gang Chen, PhD (1) · Heather J Symons (1) · Jeremy Ramdial, Ramdial (1) · Jeremy S Connors, MD (1) · Jonathan Brammer, MD (1) · Joseph Rosenthal, MD (1) · Kenneth Meehan, MD (1) · Koen van Besien, MD, PhD (1)
PMID 22517900, PMID 22796534, PMID 24319166, PMID 24319167, PMID 24842530, PMID 25797174, PMID 26359881, PMID 2889870, PMID 36195441, PMID 39382091
P01HL122173 (1), U01AI063594 (1), U10CA180886 (1), U10HL069294 (1)